Tirzepatide has potential to drive weight loss market dramatically, sa


US pharma major Eli Lilly (NYSE: LLY) recently announced top-line
results of tirzepatide from its SURMOUNT-1 Phase III clinical
trial, which has stirred up the outlook for the pharmacological
weight management market, a sector now dominated by Denmark’s
Novo Nordisk (NOV: N).

The participants taking tirzepatide drug lost up to 52 pounds
(24kg) in the 72-week Phase III study, with 63% of participants
taking tirzepatide 15mg achieving at least…

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

 

Try before you buy

• All the news that moves the needle in pharma and biotech.
• Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
• Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

• Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
• Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
• Daily roundup of key events in pharma and biotech.
• Monthly in-depth briefings on Boardroom appointments and M&A news.
• Choose from a cost-effective annual package or a flexible monthly subscription.

Be the first to comment

Leave a Reply

Your email address will not be published.


*